Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells.
cannabinoid receptor 2
neuroblastoma
selective CB2R agonists
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
07 May 2022
07 May 2022
Historique:
received:
05
04
2022
revised:
03
05
2022
accepted:
04
05
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
1,8-naphthyridine-3-carboxamide structures were previously identified as a promising scaffold from which to obtain CB2R agonists with anticancer and anti-inflammatory activity. This work describes the synthesis and functional characterization of new 1,8-naphthyridin-2(1
Identifiants
pubmed: 35566369
pii: molecules27093019
doi: 10.3390/molecules27093019
pmc: PMC9101764
pii:
doi:
Substances chimiques
Cannabinoid Receptor Agonists
0
Cannabinoids
0
Receptor, Cannabinoid, CB1
0
Receptor, Cannabinoid, CB2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Med Chem. 2009 Jun 25;52(12):3644-51
pubmed: 19435366
Sci Rep. 2017 Feb 13;7:42157
pubmed: 28191815
FEBS J. 2013 Dec;280(23):6223-32
pubmed: 24112551
Mol Med Rep. 2019 Dec;20(6):5100-5110
pubmed: 31661120
J Biol Chem. 2006 Dec 22;281(51):39480-91
pubmed: 17068343
Sci Rep. 2020 Nov 23;10(1):20405
pubmed: 33230154
Biochim Biophys Acta Proteins Proteom. 2019 Jun;1867(6):637-644
pubmed: 30710643
Cell Tissue Res. 2018 May;372(2):277-286
pubmed: 29305654
Breast Cancer (Dove Med Press). 2016 Apr 15;8:59-71
pubmed: 27186076
Nat Rev Cancer. 2013 Jun;13(6):397-411
pubmed: 23702928
Nat Genet. 2015 Aug;47(8):864-71
pubmed: 26121087
Molecules. 2021 Dec 23;27(1):
pubmed: 35011295
Cell Mol Life Sci. 2016 Dec;73(23):4449-4470
pubmed: 27402121
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Eur J Med Chem. 2012 Jun;52:284-94
pubmed: 22483967
Nat Commun. 2020 Jan 3;11(1):71
pubmed: 31900415
Cell Death Dis. 2015 Oct 15;6:e1909
pubmed: 26469958
Oncoscience. 2015 Feb 09;2(2):131-41
pubmed: 25859556
Arch Pharm (Weinheim). 2015 Dec;348(12):837-60
pubmed: 26548568
Neuropsychiatr Dis Treat. 2008 Oct;4(5):847-53
pubmed: 19183777
Drug Des Devel Ther. 2019 Oct 11;13:3539-3550
pubmed: 31631978
Eur J Med Chem. 2017 Mar 31;129:12-26
pubmed: 28219046
Bioorg Chem. 2021 Mar;108:104586
pubmed: 33607574
Cancer Genet Cytogenet. 2006 Nov;171(1):31-8
pubmed: 17074588
Front Oncol. 2019 Jul 12;9:564
pubmed: 31355131
J Mol Neurosci. 2016 Apr;58(4):441-5
pubmed: 26842917
Mol Cancer Ther. 2009 Nov;8(11):3117-29
pubmed: 19887554
J Med Chem. 2014 Nov 13;57(21):8777-91
pubmed: 25272206
PLoS One. 2013 May 01;8(5):e62511
pubmed: 23658734
Int J Mol Sci. 2018 Jul 04;19(7):
pubmed: 29973514
FEBS J. 2013 May;280(9):1918-43
pubmed: 23551849
J Cancer Res Ther. 2012 Oct-Dec;8(4):549-54
pubmed: 23361273
Neuropharmacology. 2004;47 Suppl 1:345-58
pubmed: 15464149